Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| MGF (Mechano Growth Factor) | Thymosin Alpha-1 | |
|---|---|---|
| Category | Growth Factors | Growth Factors |
| Standard Dose | Research indicates 100-200 mcg per injection site, administered bilaterally into target muscles immediately post-workout. | Research indicates 1.6 mg administered twice weekly via subcutaneous injection. |
| Timing | Immediately post-workout (within 5-10 minutes) for optimal satellite cell activation. Must be injected directly into the trained muscle. | Morning administration preferred. No food timing restrictions. |
| Cycle Duration | 4-6 week cycles. | 8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance. |
| Evidence Level | animal_plus_anecdotal | strong_human |
MGF is the E domain peptide of the IGF-1Ec splice variant, produced when the IGF-1 gene is mechanically spliced in response to muscle damage or exercise. It activates satellite cells (muscle stem cells), promoting their proliferation and preventing premature differentiation. After exercise/injury, IGF-1 gene is first spliced toward MGF (proliferation phase) then shifts to IGF-1Ea (differentiation phase). MGF uniquely drives the initial proliferative response, expanding the pool of myogenic precursor cells before they fuse with existing muscle fibers.
Research indicates 100-200 mcg per injection site, administered bilaterally into target muscles immediately post-workout.
Immediately post-workout (within 5-10 minutes) for optimal satellite cell activation. Must be injected directly into the trained muscle.
4-6 week cycles.
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus that acts as a pleiotropic immune modulator through Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) on myeloid and plasmacytoid dendritic cells. It activates downstream IRF3, NF-kB, p38MAPK, and MyD88 signaling pathways to promote cytokine production. It modulates TNF-alpha, IFN-gamma, and IL-2 in CD4+ and CD8+ T lymphocytes by upregulating CD40/CD40L and downregulating PD-L1/PD-1 expression, enhancing both innate and adaptive immunity.
Research indicates 1.6 mg administered twice weekly via subcutaneous injection.
Morning administration preferred. No food timing restrictions.
8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →